Therapeutic
Solutions International Signs Agreement
for Licensing
JadiCell's Universal Donor Adult Stem
Cell Product
for Chronic Traumatic Encephalopathy and
Traumatic Brain Injury
Company intends to
use Stem Cells under new Right to Try law for
CTE
Oceanside, CA -- December
10, 2018 -- InvestorsHub NewsWire -- Therapeutic Solutions
International, Inc., (OTC Markets:
TSOI) announced today the signing of an
agreement between TSOI and Jadi Cell LLC for licensing of the Jadi
Cell universal donor adult stem cell, as covered in US Patent No.:
9,803,176 B2 for use in Chronic Traumatic Encephalopathy (CTE), and
Traumatic Brain Injury (TBI).
The Jadi Cell product,
which belongs to the mesenchymal stem cell (MSC) family of cells,
is a unique adult stem cell, which produces higher levels of
therapeutic factors compared to other stem cells. The cells have
demonstrated safety in animal models and pilot human trials. The
Jadi Cell product is generated from umbilical cords, which are a
source of medical waste and available in large quantities at
inexpensive prices.
Chronic Traumatic
Encephalopathy (CTE) is caused by repetitive
concussive/sub-concussive hits to the head sustained over a period
of years and is often found in football players. The condition is
characterized by memory loss, impulsive/erratic behavior, impaired
judgment, aggression, depression, and dementia. In many patients
with CTE, it is anatomically characterized by brain atrophy,
reduced mass of frontal and temporal cortices, and medial temporal
lobe.
Traumatic brain injury
(TBI) is an insult to the brain, not of a degenerative or
congenital nature, but caused by external physical force that may
produce a diminished or altered state of consciousness, which
results in an impairment of cognitive abilities or physical
functioning.
"The team assembled by
Mr. Dixon is not only impressive, but has succeeded in developing,
patenting, and commercializing regenerative and immunological based
approaches to a variety of chronic conditions1,2" said Dr. Amit
Patel. "CTE represents a significant unmet medical need which we
believe is amenable to stem cell intervention. We are eager to work
with Mr. Dixon and his internationally renowned team in
accelerating treatments and potential cures for debilitating
conditions such as CTE and traumatic brain
injury".
"Many of my colleagues
suffer from CTE. At present there are no therapeutic approaches
that possess even the potential to reverse this terrible condition.
The cells developed by Dr. Amit Patel, for the first time, give me
hope that a treatment may be possible" said Wes Chandler, former
NFL Player of 11 seasons.
"It is my honor to work
with Dr. Amit Patel, who has a track record of successful FDA
applications and product development in the area of regenerative
medicine, to accelerate clinical translation of this new treatment
modality for patients suffering from brain injuries" said Dr. James
Veltmeyer, Chief Medical Officer of Therapeutic Solutions
International. "We plan to leverage New regulatory pathways such as
the recently approved "Right to Try" Law to deliver these medicines
as soon as possible to patients which currently have no other
options."
"We are especially
enthusiastic about clinically developing the Jadi Cell product
because of its advanced stage of development" said Timothy Dixon,
President and CEO of TSOI. "In contrast to other stem cell types,
which require years, if not decades of development before entry
into American patients, we believe that we will be treating
patients within 12 months. Currently means of isolating, producing,
scaling up, and delivery of the cells has all been worked out by
Dr. Patel and Collaborators. We are confident that coming from this
position of strength, we will be positioned ahead of everyone in
the area of regenerative medicine focusing on CTE".
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions International is focused on immune modulation
for the treatment of several specific diseases. Immune modulation
refers to the ability to upregulate (make more active) or
downregulate (make less active) one's immune system. The Company's
corporate website is
www.therapeuticsolutionsint.com.
1 https://finance.yahoo.com/news/therapeutic-solutions-receives-allowance-patent-133000041.html
2 https://immuno-oncologynews.com/2016/07/13/therapeutic-solutions-international-augmentation-cancer-immunotherapy-pterostilbene/
These statements have not
been evaluated by the Food and Drug Administration. These products
are not intended to diagnose, treat, cure, or prevent any
disease.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024